Hoth Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.65
- Today's High:
- $3.18
- Open Price:
- $2.65
- 52W Low:
- $1.52
- 52W High:
- $12.5
- Prev. Close:
- $2.71
- Volume:
- 240312
Company Statistics
- Market Cap.:
- $7.23 million
- Book Value:
- 3.014
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -51.76%
- Return on Equity TTM:
- -96.16%
Company Profile
Hoth Therapeutics Inc had its IPO on 2019-02-15 under the ticker symbol HOTH.
The company operates in the Healthcare sector and Biotechnology industry. Hoth Therapeutics Inc has a staff strength of 2 employees.
Stock update
Shares of Hoth Therapeutics Inc opened at $2.65 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.65 - $3.18, and closed at $2.68.
This is a -1.11% slip from the previous day's closing price.
A total volume of 240,312 shares were traded at the close of the day’s session.
In the last one week, shares of Hoth Therapeutics Inc have increased by +22.37%.
Hoth Therapeutics Inc's Key Ratios
Hoth Therapeutics Inc has a market cap of $7.23 million, indicating a price to book ratio of 0.4802 and a price to sales ratio of 0.
In the last 12-months Hoth Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-14100397. The EBITDA ratio measures Hoth Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Hoth Therapeutics Inc’s operating margin was 0% while its return on assets stood at -51.76% with a return of equity of -96.16%.
In Q2, Hoth Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Hoth Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-5.8 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Hoth Therapeutics Inc’s profitability.
Hoth Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.4654. Its price to sales ratio in the trailing 12-months stood at 0.
Hoth Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $11.92 million
- Total Liabilities
- $1.72 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Hoth Therapeutics Inc ended 2024 with $11.92 million in total assets and $0 in total liabilities. Its intangible assets were valued at $11.92 million while shareholder equity stood at $9.95 million.
Hoth Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $1.72 million in other current liabilities, 330.00 in common stock, $-49155654.00 in retained earnings and $0 in goodwill. Its cash balance stood at $11.54 million and cash and short-term investments were $11.57 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Hoth Therapeutics Inc’s total current assets stands at $11.88 million while long-term investments were $33000.00 and short-term investments were $24567.00. Its net receivables were $0 compared to accounts payable of $520658.00 and inventory worth $0.
In 2024, Hoth Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Hoth Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.68
- 52-Week High
- $12.5
- 52-Week Low
- $1.52
- Analyst Target Price
- $9.5
Hoth Therapeutics Inc stock is currently trading at $2.68 per share. It touched a 52-week high of $12.5 and a 52-week low of $12.5. Analysts tracking the stock have a 12-month average target price of $9.5.
Its 50-day moving average was $2.55 and 200-day moving average was $3 The short ratio stood at 1.14 indicating a short percent outstanding of 0%.
Around 122.9% of the company’s stock are held by insiders while 183.8% are held by institutions.
Frequently Asked Questions About Hoth Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer’s or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.